2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE manufacturers
|
| | 2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE Basic information |
| Product Name: | 2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE | | Synonyms: | REMACEMIDE HYDROCHLORIDE;2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE;RemacemideHCl;2-AMino-N-(1,2-diphenylpropan-2-yl)acetaMide hydrochloride;2-amino-n-(1-methyl-1,2-diphenylethyl)-,monohydrochloride,(+-)-acetamid;2-diphenylethyl)acetamidemonohydrochloride(+-)-2-amino-n-(1-methyl-;fpl12924aa;pr934-423a | | CAS: | 111686-79-4 | | MF: | C17H21ClN2O | | MW: | 304.82 | | EINECS: | | | Product Categories: | | | Mol File: | 111686-79-4.mol |  |
| | 2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE Chemical Properties |
| Melting point | 253-254° | | storage temp. | room temp | | solubility | H2O: >10mg/mL | | form | powder | | color | white to beige | | Water Solubility | Soluble to 100 mM in water | | InChI | 1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H | | InChIKey | HYQMIUSWZXGTCC-UHFFFAOYSA-N | | SMILES | Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2 |
| Hazard Codes | Xn,N | | Risk Statements | 22-41-50/53 | | Safety Statements | 26-39-45-60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | RTECS | AB4349500 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral Aquatic Acute 1 Eye Dam. 1 | | Toxicity | LD50 (calculated as base) in rats (mg/kg): ~50 i.v., ~900 orally (Muir, Palmer) |
| | 2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE Usage And Synthesis |
| Uses | Anticonvulsant (neuroprotective). | | Biological Activity | Non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC 50 = 8-68 mM). Anticonvulsant in vivo and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na + channels (IC 50 = 161 mM). | | Biochem/physiol Actions | Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels. | | in vivo | Treatment with low- and high-dose Remacemide (100 mg/kg and 150 mg/kg) delays the acquisition of audio/visual discrimination (AVD) task performance in female Sprague-Dawley rats[3]. | Animal Model: | Female Sprague–Dawley rats ( 190-210 g )[3] | | Dosage: | 100 mg/kg and 150 mg/kg | | Administration: | Orogastric gavage; once a day; 7 days | | Result: | Increased the number of sessions required to complete audio/visual discrimination (AVD) training.
|
|
| | 2-AMINO-N-(1-METHYL-1,2-DIPHENYLETHYL)ACETAMIDE HYDROCHLORIDE Preparation Products And Raw materials |
|